Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;38(6):895-905.
doi: 10.1097/QAD.0000000000003834. Epub 2024 Jan 15.

Comparison of HIV prevalence, incidence, and viral load suppression in Zambia population-based HIV impact assessments from 2016 and 2021

Lloyd B Mulenga  1   2   3 , Jonas Z Hines  4 , Kristen A Stafford  5 , Kumbutso Dzekedzeke  6 , Suilanji Sivile  1   2 , Brianna Lindsay  5 , Mumbi Chola  6 , Faith Ussery  7 , Hetal K Patel  7 , Alash'le Abimiku  5 , Sehin Birhanu  7 , Peter A Minchella  4 , Thomas Stevens Jr  4 , Brave Hanunka  4 , Tina Chisenga  1 , Aaron Shibemba  2 , Sombo Fwoloshi  1   2 , Mwiche Siame  1 , John Mutukwa  1 , Lameck Chirwa  2 , Mpanji Siwingwa  2   3 , Gina Mulundu  2   3 , Chinedu Agbakwuru  5 , Prichard Mapondera  6 , Mervi Detorio  7 , Simon G Agolory  4 , Mwaka Monze  1   2 , Megan Bronson  7 , Man E Charurat  5 ; for the ZAMPHIA 2021 Study Group
Affiliations

Comparison of HIV prevalence, incidence, and viral load suppression in Zambia population-based HIV impact assessments from 2016 and 2021

Lloyd B Mulenga et al. AIDS. .

Abstract

Background: The Zambian government has implemented a public health response to control the HIV epidemic in the country. Zambia conducted a population-based HIV impact assessment (ZAMPHIA) survey in 2021 to assess the status of the HIV epidemic to guide its public health programs.

Methods: ZAMPHIA 2021 was a cross-sectional two-stage cluster sample household survey among persons aged ≥15 years conducted in Zambia across all 10 provinces. Consenting participants were administered a standardized questionnaire and whole blood was tested for HIV according to national guidelines. HIV-1 viral load (VL), recent HIV infection, and antiretroviral medications were tested for in HIV-seropositive samples. Viral load suppression (VLS) was defined as <1000 copies/ml. ZAMPHIA 2021 results were compared to ZAMPHIA 2016 for persons aged 15-59 years (i.e., the overlapping age ranges). All estimates were weighted to account for nonresponse and survey design.

Results: During ZAMPHIA 2021, of 25 483 eligible persons aged ≥15 years, 18 804 (73.8%) were interviewed and tested for HIV. HIV prevalence was 11.0% and VLS prevalence was 86.2% overall, but was <80% among people living with HIV aged 15-24 years and in certain provinces. Among persons aged 15-59 years, from 2016 to 2021, HIV incidence declined from 0.6% to 0.3% ( P -value: 0.07) and VLS prevalence increased from 59.2% to 85.7% ( P -value: <0.01).

Discussion: Zambia has made substantial progress toward controlling the HIV epidemic from 2016 to 2021. Continued implementation of a test-and-treat strategy, with attention to groups with lower VLS in the ZAMPHIA 2021, could support reductions in HIV incidence and improve overall VLS in Zambia.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

Fig. 1.
Fig. 1.. HIV viral load suppression prevalence by province among persons living with HIV aged 15–59 years – Zambia 2016 (a) and 2021 (b).
VLS, viral load suppression.
See this image and copyright information in PMC

References

    1. The World Bank. Life expectancy at birth, total (years) – Zambia. Available at: https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=ZM [cited 2023 Jun 1].
    1. Logie D. AIDS cuts life expectancy in sub-Saharan Africa by a quarter. BMJ 1999;319;806. - PMC - PubMed
    1. World Health; Organization (WHO). Guideline on when to start antiretroviral therapy and on preexposure prophylaxis for HIV. Geneva, Switzerland; 2015. Available at: https://www.who.int/publications/i/item/9789241509565. - PubMed
    1. World Health Organization (WHO). Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva, Switzerland; 2017. Available at: https://www.who.int/publications/i/item/9789241550062. - PubMed
    1. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection. N EnglJ Med 2013; 369:1807–1818. - PubMed

Publication types